tirzepatide vs semaglutide comparison effectiveness Frontiers Semaglutide vs tirzepatide for weight

A review of GLP-1 agonist studies using the standard dose in high intracranial pressure reported: Patients should be counseled about the high likelihood of nausea and GI upset (diarrhea, vomiting, and constipation, delayed gastric emptying) especially in the first 48 weeks of therapy

Weeks 9-12: 7.5mg (0.75mL or 75 units)

They require dose escalation over weeks to months, and full therapeutic effects may not appear until you reach the maintenance dose

Key Points: Tirzepatide (Zepbound, Mounjaro) causes diarrhea primarily because its GLP-1 component alters how food moves through your entire digestive tract

Oral semaglutide formulations face bioavailability challenges - the medication must survive the digestive system to be absorbed

Actual packaging, labeling, and pharmacy may vary